PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Cerulean Associates, LLC

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Speed Drug Development - Cerulean's John Avellanet Joins with FDA Officials to Speak on QbD - Pharmaceutical companies face another hidden secret when struggling against a shrinking R&D pipeline and slow FDA approvals: data quality or lack thereof
Speed Drug Development - Cerulean's John Avellanet Joins with FDA Officials to Speak on QbD

 

NewswireToday - /newswire/ - Williamsburg, VA, United States, 2008/10/02 - Pharmaceutical companies face another hidden secret when struggling against a shrinking R&D pipeline and slow FDA approvals: data quality or lack thereof.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The little secret of drug development: record integrity can make or break you. Without data quality, you can expect nothing but delays from the FDA. That means wasted money, poor investment returns and increased executive liability. And that’s just one of the challenges facing the pharmaceutical industry’s shrinking pipeline.

Speakers from the U.S. Food and Drug Administration (FDA), Cerulean Associates and several other companies will look at the progress, challenges and opportunities facing the drug industry’s quest to speed drug development through Quality by Design. Mr. John Avellanet, Cerulean’s Managing Director, will speak on the challenges executives must overcome to ensure data integrity and regulatory approval.

Mr. Avellanet has won wide praise over the past year for his informative and entertaining presentations. Several attendees of last month’s Contract Pharmaceutical & Outsourcing Conference signed up for the two-day affair just to see Mr. Avellanet’s 45-minute presentation.

“I’d go out of my way to hear John speak on any subject just to enjoy his style of message delivery,” said Wayne Starnes, a CEO and recent conference attendee.

You can register for the webcast of this event at: PharmaQbD.com. Journalists needing an advanced copy of Mr. Avellanet’s presentation, or access to some of his other published work on speeding new drug development, may contact him directly.

John Avellanet is a leading expert, speaker and syndicated author on cost-effective compliance and quality systems. A former C-level executive for a Fortune 50 combination device and biotechnology subsidiary, he writes the monthly executive newsletter, SmarterCompliance™. In 2006, he co-founded his independent consulting firm, Cerulean Associates LLC.

Cerulean Associates LLC (ceruleanllc.com) is a small, private compliance consulting company that helps executives implement lean compliance, quality by design and effective management oversight, in part through its SmarterCompliance™ Toolkit executive coaching program.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Cerulean Associates, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Speed Drug Development - Cerulean's John Avellanet Joins with FDA Officials to Speak on QbD

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: John Avellanet - CeruleanLLC.com 
john[.]ceruleanllc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Cerulean Associates, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Cerulean Associates, LLC / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  SKS Media | SKS Associates Ltd

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)